Chapter 3. Privileged Structures and Analogue-Based Drug Discovery
- Dr. János Fischer2,
- Prof. Dr. C. Robin Ganellin3
Published Online: 22 MAY 2006
DOI: 10.1002/3527608001.ch3
Copyright © 2006 Wiley-VCH Verlag GmbH & Co. KGaA
Book Title
Analogue-based Drug Discovery
Additional Information
How to Cite
Kubinyi, H. (2006) Privileged Structures and Analogue-Based Drug Discovery, in Analogue-based Drug Discovery (eds J. Fischer and C. R. Ganellin), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, FRG. doi: 10.1002/3527608001.ch3
Editor Information
- 2
Gedeon Richter Ltd., P.O. Box 27, H-1475 Budapest 10, Hungary
- 3
University College London, Department of Chemistry, 20 Gordon Street, London WC1H OAJ, UK
Publication History
- Published Online: 22 MAY 2006
- Published Print: 20 JAN 2006
ISBN Information
Print ISBN: 9783527312573
Online ISBN: 9783527608003
- Summary
- Chapter
Keywords:
- analogue-based drug discovery;
- privileged structures;
- side effects;
- agonists and antagonists;
- drug action on target classes;
- GPCR ligands;
- nuclear receptor ligands;
- integrin ligands;
- kinase inhibitors;
- phosphodiesterase inhibitors;
- neurotransmitter uptake inhibitors
Summary
This chapter contains sections titled:
Introduction
Drugs from Side Effects
Agonists and Antagonists
Privileged Structures
Drug Action on Target Classes
GPCR Ligands
Nuclear Receptor Ligands
Integrin Ligands
Kinase Inhibitors
Phosphodiesterase Inhibitors
Neurotransmitter Uptake Inhibitors
Summary and Conclusions